Glaxosmithkline Share Price (GSK)

Show Chart Filters
Time period:
Moving Average:
Compare to:
Price 1,352.80on 10-05-2021 at 8:08:39
Change -2.80 -0.21%
Buy 1,352.60
Sell 1,352.00
Buy / Sell GSK Shares
Sponsored Financial Content
Last Trade: Sell 35 at 1,352.298p
Day's Volume: 130,404
Last Close: 1,355.60p
Open: 1,355.00p
ISIN: GB0009252882
Day's Range 1,350.80p - 1,356.20p
52wk Range: 1,190.80p - 1,742.40p
Market Capitalisation: £68,065m
VWAP: 1,354.190p
Shares in Issue: 5,031m

Recent Trades History Glaxosmithkline (GSK)

Buy/Sell Volume Trade Prc Trade Type Trade Time
Sell*351,352.298Ordinary
08:08:31 - 10-May-21
Buy*2801,352.80Automatic Execution
08:08:25 - 10-May-21
Buy*3691,353.886Ordinary
08:08:13 - 10-May-21
Buy*5821,353.20Automatic Execution
08:08:14 - 10-May-21
Buy*4611,353.20Automatic Execution
08:08:14 - 10-May-21
Buy*2501,353.20Automatic Execution
08:08:14 - 10-May-21
Buy*2381,353.60Automatic Execution
08:08:13 - 10-May-21
Sell*1211,353.40Automatic Execution
08:08:13 - 10-May-21
Sell*3891,353.40Automatic Execution
08:08:13 - 10-May-21
Buy*2001,353.33Ordinary
08:08:06 - 10-May-21

Share Price History for Glaxosmithkline

Time period:
to
Date Open High Low Close
6th May 2021 (Thu)1,342.201,352.601,335.001,342.80
5th May 2021 (Wed)1,331.001,353.801,331.001,341.50
4th May 2021 (Tue)1,338.001,350.201,331.601,332.10
3rd May 2021 (Mon)00.000.001,337.90
30th Apr 2021 (Fri)1,330.801,348.801,330.801,329.60
29th Apr 2021 (Thu)1,334.801,346.001,324.601,329.60
28th Apr 2021 (Wed)1,322.201,369.801,313.401,335.60
27th Apr 2021 (Tue)1,342.001,348.201,334.001,333.90
26th Apr 2021 (Mon)1,340.201,350.201,335.601,342.60
23rd Apr 2021 (Fri)1,345.401,349.801,335.601,342.50
22nd Apr 2021 (Thu)1,347.001,353.601,341.001,346.30
21st Apr 2021 (Wed)1,332.001,354.401,328.001,349.80
20th Apr 2021 (Tue)1,332.401,345.001,322.801,324.90
19th Apr 2021 (Mon)1,341.401,353.001,331.601,337.90
16th Apr 2021 (Fri)1,356.201,363.801,343.801,344.90
15th Apr 2021 (Thu)1,285.601,388.401,269.201,353.20
14th Apr 2021 (Wed)1,290.801,301.201,287.201,291.20
13th Apr 2021 (Tue)1,292.201,299.801,284.401,290.20
12th Apr 2021 (Mon)1,315.001,316.201,292.401,299.40

GSK - Glaxosmithkline Investor Summary

GlaxoSmithKline, or 'GSK', is one of the world's leading pharmaceutical companies researching medicines and vacines alike for the World Health Organization's three priority diseases: HIV/AIDS, Malaria and Tuberculosis. With an estimated 7% of the world's pharmaceutical market under its wing, GSK remains one of the industry leaders globally but remains committed to the research and application of life changing and marketable drugs.

If investing in science seems a little confusing and unpredictable then perhaps some of GSK's over-the-counter and more recognisable products will help to convince; these include Gaviscon and Panadol, smoking control products such as Nicorette/Niquitin and nutritional healthcare drinks such as Lucozade, Ribena and Horlicks.

On 23rd January 2009, GSK announced that it had signed an agreement with UCB S.A to acquire its marketed product portfolio in certain parts of the Middle East, Africa, Latin America and Asia Pacific, for a cash consideration of some £484 million. President of Emerging Markets at GSK, Abbas Hussain, said that "This acquisition will strengthen and expand GSK's product portfolio in these countries, helping us to meet the needs of patients, particularly in the areas of epilepsy and respiratory." Under the agreement, GSK acquires several leading pharmaceutical brands and investors will be interested to know that the commercial operations and product distribution rights included represent approximately 3-4% of UCB's 2008 expected revenue of at least £3.09 billion. At the time of Mr Hussain speaking, share prices for GSK were steady at 1,226.00p with a "strong buy" recommendation from brokers.

News about Glaxosmithkline (GSK)

Director Deals - (GSK)

News - Thursday, April 29, 2021

Jesse Goodman, Director, bought 722 shares in the company on the 28th April 2021......

Director Deals - (GSK)

News - Thursday, April 29, 2021

Charles Bancroft, Non Executive Director, bought 1,955 shares in the company on ......

FTSE 100 Latest
Value7,149.07
Change19.36


Login to your account

Forgot Password?

Not Registered